Alcohol Use Disorder & Its Treatment

1. What is Risky Use of Alcohol?

- Sometimes referred to as "hazardous use," "at-risk use," or "heavy drinking;" Alcohol consumption that puts one at risk for health consequences; not severe enough to be an alcohol use disorder though individuals with Risky Use may develop an Alcohol Use Disorder.
- Risky use defined
 - \circ Men < 65 y/o
 - On average >14 drinks per week
 - > 4 drinks on any day
 - \circ Women and adults > 65 y/o
 - On average > 7 drinks per week
 - > 3 drinks on any day
 - o Binge drinking: Associated with acute injuries due to intoxication
 - Men-5 standard drinks within 2 hours
 - Women-4 standard drinks within 2 hours
 - O What is a "drink"?
 - An accurate history can be tricky to obtain from patients. Standard drink is: 12 ounces of beer; 5 ounces of wine, 1.5 ounces of liquor

2. Who is at particular risk for an Alcohol Use Disorder?

- Younger adults
- o Males: 2-3x's M vs F
- Native Americans
- o Adults with significant disability, other substance use disorders, or a mood disorder

3. What are common screening methods that can be used?

- SBIRT recommends the AUDIT-C
 - O How often do you drink alcohol?
 - How many drinks do you typically have when you drink?
 - How often do you have 5 or more drinks on one occasion?
- Could use CAGE screen
- Biological markers that may indicate problematic alcohol consumption are elevated liver enzymes.
 Elevated GGT in conjunction with increased MCV, is highly sensitive for alcohol intake above normal parameters

4. What are the Treatment Goals?

- Research studies suggest a small number of patients may be able to resume normal or controlled drinking. This is an
 area of controversy. Controlled drinking is probably more likely for people with a mild disorder, not for a more
 severe disorder. Advocates for a harm reduction approach argue that for some patients this is an achievable aim
 which reduces risk to patients.
- Psychosocial treatment short term goals:
 - o Support adherence to medication for Alcohol Use Disorder
 - o Promote participation in other psychosocial services
 - Involve family, community, and employment resources
- Overall goals (short and long term)
 - o Encourage and support abstinence (or reduction in alcohol use)

5. What Treatment Options are available?

Continuing Care Approach to Treatment

- Recognition that addiction is often chronic and relapsing.
- Emphasizes modifications in the intensiveness of treatment and the monitoring as the illness waxes and wanes
 over time.

A. Psychosocial Interventions

- Brief Intervention
 - Effective treatments for non-dependent, at-risk alcohol use;
 - The BI part of SBIRT (<u>Screening</u>, <u>Brief Intervention</u>, <u>Referral to <u>Treatment</u>)</u>
- Motivational interviewing
 - Counseling technique for eliciting behavioral change by helping patient explore and resolve ambivalence about substance use and move through the stages of change (especially if pt in pre-contemplation and contemplation stages)
 - o May be used in a Brief Intervention
- Cognitive Behavioral Therapy
 - Structured, goal directed form of psychotherapy in which patients learn how their thought processes contribute to their behavior.
 - o Increased cognitive awareness is combined with techniques to help patients develop new and adaptive ways of behaving which in turn leads to changes in their thoughts and emotions.
 - CBT is found to have modest positive effect on outcomes for alcohol and other drug dependence compared to controlled conditions and no treatment
- Residential Treatment
 - o 24 hour, drug and alcohol free environment
 - Wide variety of clinical services provided and treatment models
 - o No well-designed research trials that compare effectiveness of residential treatment to lower levels of care
- Mutual Help Groups
 - o AA (Alcoholics Anonymous) and other 12 step programs
 - Working towards abstinence through group sharing and support

B. Pharmacotherapy for Alcohol Use Disorder

- Several medications can be used to treat moderate-to-severe Alcohol Use Disorder leading to reduced heavy drinking and increased days of abstinence; there is little evidence for the effectiveness of medication in treatment of Risky alcohol use or mild Alcohol Use Disorder.
- Ideal patient for treatment with medication
 - o Current, heavy use and ongoing risk for consequences from use
 - Motivated to reduce alcohol intake
 - o Prefer medication along with, or instead of, psychosocial intervention
 - o No medical contraindications to the individual drug

First line medications

- Naltrexone
 - Mechanism of Action: Exerts effects by blockade of the mu-opioid receptor. Endogenous opioids are involved in the expression of alcohol's reinforcing effects
 - May be started while patient is still drinking
 - disulfiram (Antabuse) needs to be started in abstinent patients;
 - acamprosate (Campral) ideally is used once abstinence is achieved
 - o Decreases alcohol cravings
 - o Cannot be given to patients taking opioids
 - Contraindicated in patients with significant liver disease
 - May cause liver enzyme elevation; periodically monitor liver enzymes during naltrexone treatment
 - Available in long acting injectable (depot) form of Vivitrol (cost issues, is expensive)

• Acamprosate (Campral)

- o Mechanism of Actions: Proposed anti-drinking mechanism is modulation of glutamate neurotransmission.
- Multiple meta-analyses show reduction in alcohol consumption compared to placebo, a reduced rate
 of returning to drinking, and an increased cumulative abstinence duration.
- o While useful for Alcohol Use Disorder, not found to have a significant effect on Risky/Heavy Drinking.
- Excreted mostly unchanged by the kidneys; contraindicated in patients with renal failure but can be used safely in patients with liver disease.

Second line medications

- Disulfiram (Antabuse)
 - Mechanism of Action: Inhibits aldehyde dehydrogenase and prevents metabolism of alcohol's primary metabolite, acetaldehyde. Acetaldehyde accumulation in the blood causes unpleasant effects.
 - Needs to be started in abstinent patients
 - After stopping the medication, the duration of drug's activity may be as long as 2 weeks.
 - Study suggests disulfiram is most effective when routinely taken under supervised conditions;

Off label/not FDA approved

- Topiramate (Topamax)
 - Some studies show it decreases alcohol use in patients with moderate-to-severe Alcohol Use Disorder.
- Gabapentin (Neurontin)
 - Some studies support use in treatment of patients with moderate-to-severe Alcohol Use Disorder;

C. Combining medications

• Offers possibility of more effective treatment but research trials have shown mixed results. Medication combination no more effective than naltrexone alone.

D. Medications vs Psychosocial Treatments

Are no clinical trials that directly compare medications to psychosocial interventions

E. Combining Medication with Psychosocial Treatments

- Evidence is mixed as to whether the combination of medication and psychosocial treatment is more effective than medication alone.
- Studies have generally not found that combination of CBT and medications for moderate-to-severe Alcohol Use Disorder to improve outcomes versus either intervention individually

Opioid Use Disorder Treatments

Opioid Use Disorder:

Those with an opioid use disorder typically use heroin 2-6 times per day

IV use is rapid, most efficient means to produce euphoria; IV use, most heroin overdoses. More overdoses than intranasal, smoking, or PO

Intranasal use is rapid enough to produce euphoria

Smoking is the fastest route for delivering the drug to the brain

- Intoxication
 - Natural or synthetic opioids, act at 1 of the 3 main opioid receptor systems (mu, kappa, delta)
 - Central nervous system depressant effects
 - Activation of mu receptors in the CNS results in depressant effects (respiratory depression), analgesia, and miosis. Also have the potential to cause euphoria.
 - Signs of Opioid Intoxication
 - Pinpoint pupils, drowsiness, slurred speech, impaired cognition
- Tolerance
 - Many users start out using heroin to get high but then need larger and larger amounts to get the same effect; Gets to the point where they must use simply to avoid withdrawal
- Withdrawal
 - Watering eyes, runny nose, yawning, muscle twitching, hyperactive bowel sounds, piloerection
- Typically a chronic, relapsing illness associated with significantly increased morbidity and mortality
 - o Mortality: increased mortality vs. general population, primarily due to overdose and trauma

Treatment Options

- Often require long term treatment to prevent relapse: In general, abstaining from heroin for at least one year suggests a favorable prognosis for remaining abstinent again for a significant period of time.
- First line treatment: an opioid agonist: methadone or buprenorphine
 - Suppress craving and withdrawal symptoms
 - Block effects of other opioids
 - Studies show association of treatment duration with lower rates of mortality
 - O Buprenorphine is preferred over methadone due to it being safer than methadone
 - Methadone tends to be more efficacious than buprenorphine
- First line alternative: naltrexone PO and LAI (long acting injectable)
 - If highly motivated pt;
 - o If medication use can be supervised;
 - o If pt in occupations that do not permit opioid agonist treatments
- Non-Medication options for long term treatment
 - o Individual or group addiction counseling
 - o Participation in mutual help groups such as Narcotics Anonymous

Opioid Agonist Medication Treatment

- Methadone
 - o long acting opioid agonist, binds to mu receptors
 - o also reduces euphoric effects of subsequent opioid use
 - treatment associated with reduction in spread of HIV
 - Adverse effects
 - Cardiac arrhythmias: qTc prolongation
 - Hyperalgesia-chronic use may result in increased sensitivity to pain within a month of starting chronic therapy
 - Potential for overdose-since full agonist, higher risk for OD vs. partial agonist buprenorphine
 Significantly higher risk of abuse and lethal overdose compared with buprenorphine
 - Drug-drug interactions-based on p450 system; many meds may induce or inhibit

Methadone Administration

- O Dosing can vary widely among patients and doses do not correlate well with blood levels
- o Relatively low dose (20-30 mg) can attenuate acute opiate withdrawal but is usually not effective at suppressing craving and blocking the effects of other opioids
- O Dosing for opioid addiction differs significantly from doses used to treat chronic pain
- Patients who take alcohol or benzodiazepines are more likely to become sedated and have risk of respiratory depression

• Buprenorphine

- Partial mu agonist with high affinity for the mu-opioid receptor; can displace full agonist opioids from the receptor and precipitate opioid withdrawal; thus pts need to be abstinent from opioid use for a sufficient period before starting this treatment
- With naloxone (an opioid antagonist)
 - Buprenorphine is typically given in combination with naloxone in its oral form because naloxone has poor oral bioavailability and has little to no activity when administered sublingually; If given parenterally though, naloxone can precipitate withdrawal; this prevents people from attempting to abuse the combination drug by crushing the tablets and dissolving them for IV injection.
- Like methadone, considerable variability among patients in the dose given and blood levels produced
 - Not detected by the standard urine drug screen; needs specialized assay to detect.
- Adverse consequences
 - Respiratory depression is typically negligible from buprenorphine alone; is seen when used in combination with other substances, especially alcohol and/or benzodiazepines
 - Lower potential for overdose than methadone
 - Can precipitate opioid withdrawal; thus pts need to be abstinent from opioid use for a sufficient period before starting this treatment

The source of this material is Up-To-Date.

Bold font-definitely know; Regular font-know; Italics font-supplemental

Opioid Antagonist treatment

- o Naltrexone: Prevents users from experiencing opioid intoxication or physiologic dependence
- o Used for maintenance treatment and to prevent relapse in opioid use disorder

Cocaine Use Disorder

Treatment of Stimulant Use Disorders (cocaine, methamphetamine, amphetamine)

- No medications have been shown in randomized trials to be consistently efficacious for stimulant use disorders.
- Only psychosocial interventions have proven efficacy in reducing stimulant use, but these treatments alone are insufficient for many patients.

Cocaine Mechanism of Action

- Enhances dopamine activity by blocking the monoamine (dopamine, norepinephrine, serotonin) pre-synaptic re-uptake pumps.
- Cocaine's psychological effects and abuse liability are due to enhancement of brain dopamine activity especially in the corticomesolimbic dopamine reward circuit.
 - o Intoxication effects include: increased energy, alertness, and sociability; elation or euphoria; decreased fatigue, decreased need for sleep, decreased appetite. (Sounds like a manic episode!)

Cocaine and psychiatry related disorders

- Current cocaine users twice as likely to have symptoms of depression or anxiety as non-users With increased dose, duration of use, or more efficient route of administration
 - o Dysphoric mood, panic attacks,
 - o Also grandiosity, impaired judgment, suspiciousness/paranoia/psychosis
 - In cocaine use disorder:

80% patients report psychotic symptoms Visual & tactile hallucinations >> auditory hallucinations

- Associated with variety of movement disorders
 - Sterotyped behaviors, acute dystonia, choreoathetosis, and akathisia, buccolingual dyskinesias, Tardive dyskinesias
 - Cocaine users are at increased risk of acute dystonic reactions from antipsychotic medications
- Chronic use
 - o Associated with cognitive impairment; will persist for at least several weeks of abstinence.
 - Cessation of heavy use results in withdrawal syndrome with prominent psychological features (depression, anxiety, anhedonia, fatigue, increased appetite, increased sleep) but usually mild physical symptoms.
 - Usually resolves in 1-2 weeks without treatment.

Urine Drug Testing

	Detection window for Urine test	
Amphetamines	2-3 days	
Cocaine	2-3 days	May be positive for up to 2 weeks after chronic heavy use
Marijuana	1-7 days	May be positive for 1 month with chronic moderate to heavy use
Opiates	1-3 days	
Phencyclidine	7-14 days	

Substance Induced Psychosis

- Psychosis may result from use of prescribed stimulants, alcohol, cocaine, PCP and other hallucinogens, methamphetamines, designer drugs (synthetic cannabinoids--K2, Spice) or withdrawal of alcohol or benzodiazepines
- Most instances of drug induced psychosis the substance is detectible; however cases of persistent psychosis for days
 or weeks after a drug is cleared have been described (especially with hallucinogens and amphetamines)